VKTX - Earnings call 4 2023 | Viking Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 7, 2024. I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead.

Stephanie Diaz

Hello, and thank you all for participating in today's call.

Brian CFO. President is Greg CEO; today Viking's Zante, me Lian, and Viking's and Joining

begin, like XXXX, development regarding we of of conference milestones. statements Before XXXX I'd and the activities, the call during comments under about Litigation today, time this U.S. made including Private lines February Reform harbor statements its X, safe will Securities forward-looking to contain provisions caution Act that expectations Viking's

of to differ statements as the could results Forward-looking Exchange performance. subject update undertakes cause today. you and results made speak reported and to concerning an the date, statements as only future obligation to considered with and that all uncertainties materially these encourage should company are the Securities risks company's any and of Commission, other filings and These be and statement revise or forward-looking matters. of adversely actual I not indication today's review no to

I'll Lian now turn the initial comments. Brian his for call over to

Brian Lian

Thanks, clinical afternoon to review in and update progress the for listening XX, dialed Stephanie, full ended and or the our operations. December on webcast. we'll results financial an year our with XXXX, good quarter by programs on and Today, and provide phone fourth recent everyone

demonstrated a significant of tolerability. agonist this and the highlighted we exciting an clinical during year our announced important was X trial first-in-human the favorable VKXXXX, sub-dosed receptors. dual study, with safety weight XXXX Phase statistically clinical I VKXXXX a In GIP of loss and from positive from for with by year, GLP-X of to releases program, obesity our Viking, results X data programs. respect With

VENTURE the evaluate Phase Following with in further these to obesity. VKXXXX results, II trial patients initiated called we

this line We results this study to quarter. expect top later report from

formulation year, we VKXXXX. of oral trial, Phase the an clinical also During evaluating I a initiated

to expect this study from later this results quarter. report We

patients study of the met programs to good This and VOYAGE in our other with fibrosis. In with the data important VKXXXX steatohepatitis positive announced endpoint receptor significant beta trial year results statistically during the line from other placebo. as reductions made hormone study forward the from look XX-week as Phase XXXX. with Viking agonist, top well. compared its with pipeline demonstrating patients this patients progress primary biopsy nonalcoholic first IIb we May, biopsy-confirmed half receiving in treated We well reporting fat liver with as measures VKXXXX of in thyroid

our will be activities used which operations to support and year of proceeds financial funds managing the financial provide to successful results completed XXXX a the of we details our further sheet, gross review development multiple XXXX. On expenses, our with with pipeline public fourth we resulted milestones. I'll $XXX continued in through strong approximately million. after in full stock, common side, of balance along a These diligence our on thanks continued for the advancement programs quarter clinical and offering

turn With call I'll Financial Zante, to over Greg Chief the that, Viking's Officer.

Gregory Zante

now with go Commission, I'll quarter conjunction for ended results full beginning my results the XXXX, participants Exchange expect In that fourth over to I'd recommend the XX, to our Securities the Viking's like quarter. Brian. Thanks, and and file to we Form filing XX-K which comments, with December with the refer for today. year

in income general and in noted offset compared [Audio XXXX. expenses interest research Our and Gap] research development by the partially to increase and increased previously, administrative period expenses same

months XXXX. for December ended I'll over XX, the the now XX go results

to manufacturing The benefits period consultants, salaries for candidates, offset for third-party in development for clinical December XXXX. the partially drug were the stock-based expenses increase $XX.X same research due our services XX, million Our decreased preclinical expenses and by to increased XXXX studies, provided primarily studies. related and was related to compared expenses and ended $XX.X to million year compensation, by

ended year primarily XX, related the to administrative December to legal XXXX. due Our increase million in to were increased the for $XX and patent salaries benefits. consultants XXXX, The period $XX.X and was same compared million stock-based third-party general compensation, and expenses for and expenses services,

XXXX, by ended to income the general a in the net net XXXX. or ended to $XX.X the for $X.XX year reported per $XX.X December to share or loss XXXX, in and the compared of XX, expenses previously, net and per share same increase a loss XXXX. in and million $X.XX administrative year million the offset Viking increase due For expenses period loss XX, development increased December interest was corresponding research of in noted period primarily in compared The partially

of cash the XXXX, December $XXX to of short-term as to investments million At million December balance equivalents XX, XX, Turning cash, sheet. Viking $XXX XXXX. and compared held

financial concludes to my I'll now over and the turn call review This Brian. back

Brian Lian

Thanks, Greg.

review objectives As key programs, X clinical I'll in the XXXX, our and mentioned accomplishments in comments, with opening our I positioning significant for made progress for briefly each my Viking an preview exciting XXXX ahead. of year XXXX. now company

designed and as was agonist the results pharmacokinetic This on with safety, begin fat. initial update VKXXXX. or single study receptor. In GIP evaluate ascending potential positive study of liver is exploratory profile measures, Viking's glucagon-like VKXXXX weight polypeptide, compound impact XXXX, compound's glucose-dependent I'll Phase dose newest its multiple a dose as our insulinotropic a from program for the to and including and announced I body peptide-X, on VKXXXX of and the quarter metabolic well dual stage GLP-X tolerability or ascending obesity. clinical of is an the we receptor first and

VKXXXX single XXX hours excellent therapeutic well of women and and half-life The single that displayed safe tolerated and favorable the approximately of study demonstrated of XXX to ascending dose and men pharmacokinetics. a portion doses hours VKXXXX were exposures. healthy enrolled subcutaneous and demonstrated

study and mass index subcutaneous multiple The of for per portion doses weekly days. VKXXXX These enrolled squared. of with meter subjects ascending of this minimum dose a body XX women men XX once kilograms healthy received

dose clinical ascending the study dose multiple date, demonstrated safety positive of and in tolerability the encouraging As activity. and single signs ascending

to weight of in demonstrated VKXXXX day body to XX in significant reductions ranging X%. relative Statistically up weight mean last receiving placebo dose after from days compared VKXXXX body point, administered. XX X.X%. maintained demonstrated cohorts to improved time follow-up the baseline to ranging was in or also at differences up the reductions receiving were weight Cohorts VKXXXX also placebo, body All

reported fat plasma With of VKXXXX's events moderate. respect XX% to lipids. and ascending safety mild tolerability, of This adverse in study portion multiple observed moderate. study events mild the the also or reported XX% and encouraging on liver or of adverse as And dose impact were demonstrated as gastrointestinal-related were

reported the results to XX% up X baseline. reductions liver with trial Phase subcutaneous fatty Specifically, of reached of Among in liver potential doses weekly fat placebo-adjusted subjects after VKXXXX, VKXXXX's with benefit various approximately disease, nonalcoholic These of indicate disease. from patients in subjects forms fatty fat XX%. reductions in I liver liver

with our continue Week of results development. from this to levels. levels oral of baseline the last to with baseline at cholesterol to in an for VKXXXX and normal the These Obesity as and served plasma to featured study were to basis study healthy treatment that further fact program by reduced of advance XX%. of were decision interesting produced presentation the volunteers total respect also in These in plasma October apolipoprotein particularly lipid began these cholesterol data lipids, encouraging reductions XX% XX%. up light LDL to B Plasma up in reductions With up in are clinical

tolerability, designed pharmacokinetics and weight adults administered the loss VKXXXX trial the least subcutaneously evaluating with end, last enroll was to study to approximately third with multicenter XXX this the condition. with efficacy at for evaluate adults The obesity is To are safety, weekly or placebo-controlled year, once of II VKXXXX comorbid Phase double-blind, This patients in is VENTURE weight-related that of VENTURE who initiated quarter weeks. randomized, trial Viking in X XX overweight trial obesity. a

the from the week is in interest, weekly Due patients baseline of endpoint compared ascending will higher-than-expected Phase VKXXXX multiple enrollment trial's patients clinician with schedule. VENTURE XXX among assess up to placebo. evaluated and ahead to subcutaneous The of to the XX top to and XX-milligram dose I the compared The XX trial prior primary study. change with dose of patient was weight body as increased in doses milligrams this evaluating to percent VKXXXX of treated completed study

exploratory and efficacy range measures. a will evaluate safety endpoints of Secondary additional and

We from in to results study the report year. the this top line this first expect quarter of

of of Subjects of of I squared. extension study study of The have of a index will placebo-controlled a the oral following the the quarter the in per receive the multiple double-blind, year, VKXXXX, the for is mass of randomized, tolerability of initiation days first oral meter This addition dose evaluate of is and moment novel single of dosing. in objective kilograms portion clinical in discussed study In a safety, of XX minimum announced dose subcutaneous VKXXXX ago. tablet this study days. volunteers Phase a once-daily study The evaluating Phase doses is formulation I an XX this and molecule. to the Viking who ascending last pharmacokinetics VKXXXX oral to of study study XX the ascending body portion healthy a formulation primary

pharmacodynamic Exploratory in weight markers. and endpoints other body include changes

study report from We results quarter the this to this in year. the first expect of

the for thyroid treatment an is an beta of isoform on fibrosis. as hormone small molecule the our orally provide VKXXXX well VKXXXX and now update available tissue NASH liver that is as the the of I'll selective for program of receptor. agonist receptor

with density least liver magnetic announced May, VOYAGE Last included efficacy, in as VOYAGE Phase Enrollment biopsy-confirmed proton trial of a results fat from ongoing assess well fraction multicenter as fat VKXXXX. fibrosis. designed NASH double-blind, and content resonance study and FX line international fibrosis. to at study measured FX The patients top and as tolerability the VKXXXX patients of by is with positive we safety X% placebo-controlled imaging the IIb randomized,

from XX% up with placebo. to patients reported May, liver XX% liver achieved in significant fat level of likelihood demonstrating least fat. VKXXXX is we patients to baseline from histologic with XX% of reductions VKXXXX liver ranged successfully As VKXXXX study This receiving reduction XX as to associated benefit endpoint a among The in patients in with receiving XX% efficacy from fat content at median experienced in greater of compared receiving primary in Importantly, NASH. a week relative baseline its change statistically relative this

atherogenic that statistically proteins. cholesterol, results benefits. believe and As LDL in has We cardiovascular these prior significant provide to indicate long-term in achieved VKXXXX the VKXXXX-treated triglycerides potential studies, reductions also patients

events demonstrated served particular, establish excellent XX% safety treatment promising among discontinuation gastrointestinal In initial arms. adverse due VKXXXX's adverse low mild VKXXXX of treatment-related profile. moderate, to and were events VOYAGE and The tolerability also placebo VKXXXX data or further among as patients receiving to tolerability. and balanced reported

from American this fibrosis. similar diarrhea, study, those nausea, frequency to presented as liver vomiting In and with compared at of Viking FX stool for Study data Annual Diseases. study rates Association placebo. patients the X new the Liver the demonstrated November, well VOYAGE VKXXXX-treated were the data new In of These Meeting or having among or without as FX of patients the reductions diabetes robust fat type among

fat suggest Among liver X which to XX, reported reductions patients the type the diabetes. ranged These week liver patients diabetes the reducing at with comparable NASH. in X of from from to reductions XX% observed with in among an activation without baseline at of that effective fat was type hormone XX% thyroid metabolic presence remains data comorbidity in commonly important beta patients receptor

the potent reductions FX nor fibrosis. presence neither impacted efficacy Thus, or with VKXXXX's or fat. in liver the among also fat meaningfully presence FX VKXXXX reducing liver FX demonstrated fibrosis patients FX of of X with type Treatment diabetes in

are to suggest believed drivers important be key benefits these NASH, in results subgroups. lipotoxicity underlying and across steatosis As long-term

on XX VOYAGE after completed data changes the We in in recently and reporting half biopsies weeks assessed study histologic the XXXX. forward first final look of the of treatment to

orphan Moving to [ program. ] our disease

adrenoleukodystrophy long-chain genetic fatty metabolic second of function that Our patients isoform being is transporter disable beta is patients Ib evaluated VKXXXX, peroxisomal X-ALD. orally VKXXXX hormone VKXXXX, receptor small thyroid Phase the is in X-linked Like caused agonist, is trial or debilitating and beta also acids. rare by molecule hormone of the disorder the is of that an that a currently in thyroid with selective for very receptor. available X-ALD

As is a and long result, metabolize very fatty are the to acids efficiently onset compounds chain contribute of and patients to X-ALD. the of progression these unable believed to accumulation

apolipoprotein and once-daily no accumulation, measures. treatment LDL anticipated or I encouraging GI tolerability received demonstrated reported VKXXXX evidence dose-dependent lipoprotein cardiovascular with signals serious adverse events an signs vital the profile also a A. triglycerides, consistent experienced no B demonstrated and exposures, study, to reductions with or and Phase side prior VKXXXX In half-life effects, of dosing. Subject and safety observed in dose-related no for cholesterol, VKXXXX

AMN. days. The patients the acids. form patients is The multicenter very a in common evaluate the to changes adult safety, ongoing with exploratory of X-ALD, objectives most study XX pharmacokinetics levels Phase daily The Ib or includes fatty of of This form is are of study of disorder. in the adrenomyeloneuropathy the for in an placebo-controlled plasma study randomized, trial conducted the orally is which of AMN long-chain with assessment double-blind, administered VKXXXX being VKXXXX tolerability study primary and of once also male

We expect of results top line report from XXXX. in the to half study the this first

and productive the our for company programs. progress year In clinical with conclusion, XXXX with achieving an each Viking, was exciting significant of

and which the results early year, of the first efficacy well I promising tolerability. as safety trial VKXXXX, signals reported demonstrated of the During we from Phase as

of evaluation expand we I Phase the for VKXXXX, formulation market initiated also the which this opportunity oral of compound. a may novel believe We clinical

initiated enrollment data VKXXXX's II patients I of of VENTURE formulation II upsized to evaluate fall the Phase later longer-term the with this in forward oral the study along the Phase In look study. completed We quarter, from XXXX, to reporting clinical with the benefit obesity. and VENTURE the Phase the results trial from we

reporting safety forward on NASH best-in-class beta IIb this from biopsy-confirmed endpoint and The successfully to VOYAGE Phase We agonist, in VKXXXX's with favorable effect and thyroid study study VKXXXX its from tolerability affirmed primary fibrosis. along our fat data also initial the data look the liver achieved profile. and of receptor

XXXX. biopsy the half XX-week study in from first the this of report to expect We data

for results Ib VKXXXX the of study the the in Phase of forward first this and look trial adrenomyeloneuropathy to from we continues, treatment announcing later also The half.

completed we our sheet a will with and position objectives XXXX support and XXXX Finally, balance strong a beyond. cash for that

our Thanks Operator? prepared us comments for call partners, to at shareholders, and and like extend of trials questions. our All joining us, support. the our This the optimistic continued importantly, are in for much the we'll for ahead and patients thanks today. Viking our their clinical to would open about investigators year now participating concludes for very

Operator

And our comes Truist. Instructions] Lee question [Operator first of from Joon

Joon Lee

the Regarding I, weeks. just weight in VKXXXX, Phase in you X% reminded you us X placebo-adjusted loss subcutaneous saw that

what's to weeks using in So dose, trial? expectation to of with rate XX dosing longer upcoming up up the loss XX% reasonable VENTURE a of higher

Brian Lian

Yes. Joon, thanks the for questions.

VENTURE So study. we're really using for hurdle around an the X%

forward. be if us think to we sufficient showed would that, I for that move

XX I think weeks. it could be competitive at

Joon Lee

and you be looking quick a just should tracking in the efficacy for that are And VENTURE follow-up. we What safety out measures other trial?

Brian Lian

what? other I'm sorry, what safety and

Joon Lee

Efficacy measures.

Brian Lian

and insulin, Efficacy. Yes. We're standard looking lab at, obviously, plasma lipids. nothing We're looking the safety battery it's at plasma assessments in a or analysis. exotic But as safety glucose, Cardiovascular unusual same, chemistry. clinical well. of pretty

Joon Lee

last Great. And then X one. quick

XX able than whether to oral the you VKXXXX, milligrams disclose dosed the in For are higher you've [indiscernible]?

Brian Lian

the the disclose details those cohorts. not We'll we're details we No, to going into disclose of when get all the of data.

Operator

The comes Seedhouse Raymond Steven James. of next question from

Steven Seedhouse

Can hear guys. that, now? about Sorry you me

Brian Lian

can. we Yes,

Steven Seedhouse

Sorry, my ask VENTURE. first apologies. I to about wanted

were get titration weeks, schema X.X following you XX-milligram if still dose high X to cohort, the just higher case, dose. titrated, you in like this milligrams the every wouldn't particularly the For the arms, tirzepatide

curious of So titration the for clarify like what can are study? just dose schema sort if the increments in that you and

Brian Lian

blocks. Yes. lowest X.X use a for We dose XX weeks. mgs X-week The is

starts for milligrams The second for weeks X the And for milligrams so X for X dose X then And X X milligrams XX dose XX-milligram milligrams for X or weeks. X X then and is then XX weeks, XX is XX then weeks -- weeks. dose X.X at weeks. weeks, weeks. -- X The for for it's for mgs X.X X XX-milligram and X weeks.

Steven Seedhouse

to study are drug, then the off curious -- the analyzing data? I'm follow-up X-week that's Perfect. weeks on X-week line XX Appreciate waiting that period that drug? there's the if want the conclude is would include ask top also for follow-up and in a off-drug just release And we just detail. to Or before

Brian Lian

weeks earlier the a through mistakenly, it's might we'll report yes, And when said Well, data. believe have be top have we X-week question. line X I follow-up that I follow-up period. It's a a good window. but you X-week

Steven Seedhouse

sequencing first to they is announced the comes would Okay. what And subcu data, might which first? the be the but ask, the and Or oral be well as I of together?

Brian Lian

announced No, be going not and to they'll Thanks, Yes. this both quarter. together, Steve. be

about I to is all going we're The the long. not granularity that's quarter think give. very

Operator

Olson Oppenheimer. next comes of Jay from The question

Jay Olson

Congrats of expect? we the data on progress I Can just about update. talk oral cohorts data to you have how many for since Phase you the cohorts, option add should the

Brian Lian

to was but question. trial when actually we add we'll to data. the Joon, to of thanks on all cohorts, cohorts. I details to Jay, mentioned But the of details that data. have we're not maintain numbers into designed recently The the yes, release for enroll flexibility get the until cohorts we we release going X the

Jay Olson

Novo And just might to then acquisition since expect can Catalent, planning through? your and is about I talk any you acquire guess goes you plans manufacturing if that impact

Brian Lian

Yes. Thanks. shouldn't Good don't and not plans I near in believe impact It term, us future as as at definitely well. at the -- least all, question. far as

I supply that studies be required to clinical think approval. to we're receive all set the of all would

Jay Olson

Great. you big will you weight fit Okay. for landscape? the And in oral obesity oral can just drugs the about the landscape loss and drugs current of scheme grand where think picture talk

Brian Lian

approved big the Yes. XX But That's era, faces. there's GLP-X the very, That's we're industry challenge years that question, oral a a X very Jay. into agent. and difficult

excited working a difficult. it's we're we're program about, but So on very, very

lead to commercial in would positions, a injection. doesn't an with subcu for different multiple want maybe to therapeutic start be X have a orals think as who I someone

in and a an option. you a of large setting. maintain sense, you same would the a that's to maybe take body the amount continue to one because level we be efficacy would of if the don't weight. as want off in really wouldn't potentially certain important really And loss weight to And think oral be you require subcu a transitioning attractive to that Second target come a subcu, maintenance setting

We think in the be use. the opportunity potential other would temporary

You want that. up have some to whatever, an of or you months X event lose and weight ahead in coming

necessarily need dosage the oral magnitude suitable subcu loss wouldn't you could by would weight So a that form and there. be of provided be

see market, of is lot of important see as we opportunities. the opportunity oral but different a really meat We the a the opportunity. incremental So subcu the

Operator

Rahman The next question from Group. of Naz comes Maxim

Nazibur Rahman

me. just a for and on progress Congrats couple of questions the

obviously, So busy ADC studies If Phase succeed to these half which clinical provide and context of IIb results. the you the both VOYAGE it a trial? to some the programs we would have VENTURE very, or into to advance take do cost or could color how much very were want first you you ] what [ see, next around

Brian Lian

But large programs. obviously They're $XXX not more and those expenses easily precise than aware, studies. think very to for give million the Probably these very are going say, Phase of -- more to guidance Yes. suffice than expensive on extensive is everybody I detailed study. studies, III

Nazibur Rahman

Got Do your a current, now that device vial works? it in I mechanism? you you in guess, bit Is plans or like little for you. And an syringe? injectable. a about for use auto-injector patients have the of injectable. any on an talk delivery just the Is your auto-injector Could like

Brian Lian

study is will but violent Yes, II be it is. The future VENTURE a studies. device using in syringe we different using Phase a

Nazibur Rahman

year? more on was like we might Or Is an this that get get we on update something or might that update an something 'XX?

Brian Lian

the and study we provide the of that start an on timing that when update next is probably TBD. We'll

Operator

Hsieh Blair. question next William comes The of from Andy

Tsan-Yu Hsieh

XXXX. about Congratulations look a forward progress XXXX on to question the all administration. and oral very in A productive the

there the there ] of you curious at some that oral the gastric you that water. a into Rybelsus you of absorption engineer Do restrictions? think these restrictions [ baked just the [indiscernible], If technology about potential volume is formulation. the can timing look away label, about I'm are

Brian Lian

Andy. Thanks, Yes.

subject We the study. behavior anything haven't behavior their technology the disclosed or regarding in patient in

additional say the they take we people these disclosed or requirements I per discuss when in we any trials, the just We data they but -- will haven't many morning, suggestions. their now, when Phase that are as disclose fasted doses I'll but

Tsan-Yu Hsieh

Got it.

OBC Bersani deal increase boost and assets in looking then the of interest field, ] valuation the And [ lean staying is an at there same ] Okay. recently. obviously, in [ that could body the perhaps clinical mass,

for your has pipeline, XXXX, in So obviously, demonstrated that that. potential

with prioritization So that I'm can asset us? about potentially perhaps on inbounds in that increased curious change or any external you share

Brian Lian

at FDA in clinically these from agents reasonable relevant mass. a is response. hip and and nothing the could VKXXXX clear clean but Andy. -- experience sounds the not is than and the considers question. with the Yes. and more study, have we've saw it interesting extent, right, very we the I increases do agents the it's have I maybe tell those mass In important, the 'XX. on agent, side. potent certainly, drugs, believe body It's data story it's of increase in most it's significant Thanks, XXXX great, and I that ever mean, our that approach. It's We we muscle just to reported beautiful a what you're And adding we relevant, an oral an there's building body be a is seen. in oral lean some potent is doses clinically muscle in all mass. muscle in not change dose easy muscle fracture experience lean loss And to it knowledge, know to

is area. So an it interesting

but very We necessity have got medical compound, us. potent is bit to little a murky a the

Tsan-Yu Hsieh

last this maybe one terms And fair. little That's quarter. in uptick a quick of R&D,

that foresee forward? thinking going trend you about how Just do

Gregory Zante

our assuming our think be last will all of this but programs bit, I up go year will not up and a a success. on radically, focused bit year, Andy, R&D versus it advancing

sure. a not So way up, it I think but could think you about increasing way, bit, for

Operator

Smith Leerink Thomas from Partners. comes of question next The

Thomas Smith

both in of obesity programs. you're next our front on just interest just [indiscernible] and what in development development environment, interest seeing strategic remind Maybe across active lot thinking us business very steps you those like how a ] obviously, Can NASH. just and a the on space. seems seen it of comment programs, a about terms picture. you're the there's partnership, funding We've And big [ one, of

Brian Lian

comment We high benefit we're Tom. an that Thanks, can't you're it's an of the of on on seeing active the the industry, I'd saying in say, and just these correct based that. therapies the much I awareness, magnitude too and area would that success say, across clinical area provide.

potential would would and to that be engage makes we So interest happy be in discussions. from there partners, those sense

Thomas Smith

Got it. maybe And VOYAGE. That's helpful. then on just one

You VOYAGE, patient just kind the data last Maybe evaluating us remind gating you're completed could whether thinking in us to using factors and walk reporting those a mentioned review having the line biopsies the through you're biopsies just you recently. about top just how single pathologist multipath or there set. of

Brian Lian

Thanks. Yes.

goes So a cusp made. the using. right reach final the or reader [ like a is slower is biopsies when the on things are patient before there's that an reader single to the the reader of of there. consensus something must It slide a of reader we're And and FX ] single whose first second element or a second to the reader. a activity FX NAFLD then And fibrosis X, assessment is score like go second that the biopsy

approach really started So widely the X the think we reader I used. become more before study had

And single have that's we so reader. the why

Operator

next of Laidlaw Jen & Yale comes The from Company. question

Yale Jen

here. ones quick X about Just

any ] in opening terms [ mentioned impact The in your guys data, on thoughts or I whether there's reporting thinking thinking? that, things liver overall fat. that you of Lilly the reason [ or other strategic XXXX earlier and about guys the is additional were you had actually synergy, first of given the ] NASH wonder

Brian Lian

Thanks. Not really.

interested a resolution. to have pursuing already and mechanism agonist encouraging at We appears point think effective NASH with see not the do program at NASH dual this it's I and the be to program. NASH VKXXXX really that

stick I with being exciting. to that with that's we're the think program. But for time obesity going

Yale Jen

Okay. and published that Maybe Phase any is as I one there [indiscernible] is your which there data. that any program will Amgen thoughts -- recently well? follow-up more comment Was here, their AMGXXX

Brian Lian

question. Yes. No, good

forward. good had evaluation we'll really chance to data evaluate But guess data, a fresh. I those get question haven't those But for into Amgen. moving is pretty yes, We of the

Yale Jen

Well, for all year. congrats on data the progress look half of this the the and

Operator

Joe Next Pantginis question from Wainwright. comes HC of

Joseph Pantginis

I development. just envelope start first, of push the maybe business your back commentary, at end Brian, bit little question-and-answer on the So to wanted a

happy said to may. And maturities I curious, be You may that able discuss you'd ongoing? any you the in leveled was be Are I to if of potential engage discussions just discussions.

Brian Lian

mischaracterize always open to Joe, X. that to Yes, I anything. been wouldn't statement since partnering day mislead or or discussions want We've

evaluating opportunistically whatever always us. to is presented we're So

can't any discussions. So I really characterize

Joseph Pantginis

Got Got then asked do same regarding VENTURE. was earlier ask oral I'll success? the it. is that the very And the it. you a to to benchmark what question, and consider about study, question earlier the

Brian Lian

if look yes. well, study, oral it the study. and We've For it's always could PK considered -- on obviously, tolerability and safety a

encouraging. look look PK tolerability we and could safety, for On I injectable So weight, we body clean, predictable like GLP-X if think, month, an a profile. after a that would be,

look a to at further what's being probably X% but something It's the development. so variable, that we little as X% bit there? And warrant would magnitude

Joseph Pantginis

question, beyond. or pivotal first fair. to designs? then passes Very this now take last my later plans to And XXXX even into any Are you and obviously, willing regard Okay. goes with study

Brian Lian

obesity? For

Joseph Pantginis

the NASH, For yes. in company, for obesity, for general

Brian Lian

both with data these to yes. plan programs, with yes, FDA the analysis. speak of following the we Yes, Yes,

And FDA like the NASH have But do have be will they indications, to design. idea a recommendations end So the regarding or both next potential good new on any nice the Phase look comments but meeting what Type trial those C ]. II to we'd and would program, we on to VKXXXX the we trials have And outline for with what steps [ meeting an know with talk have then a pretty of program there. with guidance learn it that FDA the is like.

Operator

] Paravano comes Jack of question [ next from The Stifel.

Unknown Analyst

], calling This is in [ Jack for Samimy. Paravano Annabel

just NASH briefly touch to wanted tirzepatide data synergy from NASH trial. So again, the resolution on I

kind receptor impacts change fitting agonist Just given the view liver results [ ] beta paradigm, those more the treatment mechanisms curious similar fat upstream if of you THR both where into that have?

Brian Lian

this Yes. of a doesn't population. The heterogeneous for targeted will used think there's patients change of We different and to very different the role our better in going of a really do lot different Thanks, view begin Jack. be is suited to be agent. population therapies. with It therapies

see That do it sort GLP-X we patient. So But in be paradigm, would targeted as backbone overweight we agent. of treatment the in the for remaining to nice there's sure. is that potentially opportunity naive a targeted think said, still relevant the for I think agents the a won't a diabetic therapeutics or see be important type

Operator

comes question Zelin Next BTIG. Justin from of

Justin Zelin

of of the on guidance into how into that? of than guidance formulation earlier patients or an be I should we to rather progress. interest oral the level subcu wanted of about Congrats XXXX or behalf -- demand just Brian, on for here thinking a ask released ahead for being

Brian Lian

No. more no -- hiccups quickly the Justin. during the thanks, trial enrolled were It the of than study. It's just expected and was just course was

And the we should quarter. this data so we have think

was Going in it size It the speed of the the and enroll. easy pretty to just -- demand, to I was trial. mean demand really the was reflected

Justin Zelin

same makes to me. and possible data the we sense on at oral on the same That the time, And date? it subcu -- get is could the

Brian Lian

quarter. than we will disclosed probably And both say to sequence, other No, the not. haven't just be this

Operator

back over I would our the like This to for to remarks. session. Stephanie Diaz concludes any conference question-and-answer closing turn

Stephanie Diaz

coming Viking for again Therapeutics. months. of forward you great a support your look continued updating Thank the in to you participation again We Have and afternoon.

Operator

Thank and you now conference disconnect. now has may presentation, today's attending concluded. The you for

Viking Therapeutics (VKTX) 7 Feb 242023 Q4 Earnings call transcript